Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Dec 20, 2023
Completion of enrolment in Neuren's Angelman P2 trial
Dec 19, 2023
Application for quotation of securities - NEU
Dec 18, 2023
Investor presentation, 18 December 2023
Dec 18, 2023
P2 trial shows significant improvements in Phelan-McDermid
Dec 14, 2023
Trading Halt
Dec 05, 2023
Neuren completes enrolment in Pitt Hopkins Phase 2 trial
Nov 20, 2023
Comment on media speculation
Nov 13, 2023
Neuren completes Phelan-McDermid syndrome Phase 2 trial
Nov 08, 2023
Investor presentation, 8 November 2023
Nov 03, 2023
DAYBUE net sales US$66.9 million in Q3 2023
1
2
3
4
5
Next